Jasper Therapeutics
JSPR
23 hedge funds and large institutions have $37.5M invested in Jasper Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 6 closing their positions.
11,700% more call options, than puts
Call options by funds: $118K | Put options by funds: $1K
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.04% less ownership
Funds ownership: 5.49% → 5.45% (-0.04%)
4% less funds holding
Funds holding: 24 → 23 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
46% less capital invested
Capital invested by funds: $69.6M → $37.5M (-$32.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$138K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$115K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$47.9K |
| 4 |
State Street
Boston,
Massachusetts
|
+$31.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$894K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$61.5K |
| 3 |
Renaissance Technologies
New York
|
-$39K |
| 4 |
VAFP
Vahanian & Associates Financial Planning
Saratoga Springs,
New York
|
-$36K |
| 5 |
Morgan Stanley
New York
|
-$3.65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$28 | +1 | +4% |
|
27
Citigroup
New York
| – | +$570 | +20 | New |
|
JSPR Hedge Fund Activity: Q2 2022 in Review
23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2022, worth a combined $37.5M — down 46% from $69.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of JSPR and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 9 added.
The largest buyer was BlackRock, adding an estimated $138K. The largest seller was Federated Hermes, exiting entirely with an estimated $894K sold.
- 23 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2022, down from 24 in Q1 2022.
- Funds reported $37.5M of Jasper Therapeutics stock for Q2 2022, down 46% quarter-over-quarter.
- 5 funds opened new Jasper Therapeutics positions in Q2 2022 and 6 closed out, a net change of -1 holder.
- The largest Jasper Therapeutics buyer in Q2 2022 was BlackRock, an estimated $138K added.
- The largest Jasper Therapeutics seller in Q2 2022 was Federated Hermes, an estimated $894K sold.
Based on aggregated 13F filings for Q2 2022.